A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia Who Are 60 Years or Older
收藏DataCite Commons2025-10-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008399/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to establish the maximum tolerated dose (MTD), and to assess the
safety and tolerability of MLN4924 (pevonedistat) in combination with azacitidine in
treatment naive participants with AML who were 60 years of age or older.
提供机构：
Vivli
创建时间：
2022-08-29
